Skip to main content
Premium Trial:

Request an Annual Quote

Michael Lucero, Amit Kumar


CombiMatrix, a Pasadena, Calif., customizable biochip company, has named Amit Kumar as chief executive officer.

Kumar, who replaces Gerald Knudson, previously served as a director of CombiMatrix and as senior vice president of Life Sciences at Acacia Research, of which CombiMatrix is a wholly owned biochip subsidiary.

He came to CombiMatrix from Signature Bioscience, where he was president and CEO. He has also worked to invest in emerging life sciences companies for Oak Investment Partners, and held positions at IDEXX Laboratories and Idetek.

Kumar received his PhD from the California Institute of Technology and completed a postdoctoral fellowship at Harvard.

As CEO, Kumar said he will focus on accelerating CombiMatrix’s development of strategic alliances and customer base, and building on CombiMatrix’s recent strategic alliances with Roche Diagnostics and NASA to develop diagnostic biochips.


Fluidigm, a South San Francisco, Calif.-based maker of flexible rubber microfluidics biochips, has appointed Michael Lucero as senior vice president of marketing.

Before joining Fluidigm, Lucero served as vice president of applications marketing and R&D for Applied Biosystems, where he implemented product development strategies and managed R&D and marketing efforts for TaqMan reagents, PCR, cellular detection, sequence detection systems, and other products.

Lucero received a BS in biochemistry and his MBA from the University of California, Berkeley.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.